- The incidence of a second primary cancer (SPC) after low-dose brachytherapy (BT) for prostate cancer is low, but there may be a small increase in the risk for subsequent bladder cancer.
- The study included 889 patients with early prostate cancer who were treated at both private and public hospitals by the same BT team, with a BT seed implant as monotherapy during a 12-y period.
- Data were prospectively collected on all subsequent SPC diagnoses.
- 60 patients (6.7%) in the cohort developed subsequent malignancies at sites outside the prostate; primarily melanoma followed by lung cancer.
- 11 pelvic tumors were considered as potential in field malignancies, including 4 rectal adenocarcinomas and 7 urothelial cancers in the bladder.
- Most of the di...